الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 190 |  |  |
| | | from | 190 | | |
Abstract
Human toxocariasis is an important worldwide soil-transmitted
zoonotic disease. Neurotoxocariasis is a serious condition that is
linked to reduced cognitive function, behavioural alterations and
neurodegenerative diseases. Unfortunately, the available drugs for
treatment of toxocariasis are with variable results. Mesenchymal stem
cells (MSCs) have been used in animal models and clinical trials of
tissue injuries and it gave promising therapeutic results.
The aim of the present study was to evaluate mesenchymal stem
cell therapy for treatment of brain organ damage caused by
experimental infection with Toxocara canis alone or in combination
with the traditional drug albendazole.
Therefore, this study was designed using forty T. canis-infected
albino mice (1000 eggs/mouse, orally) and an additional control group
(GI) (-ve control) of ten healthy mice. The infected mice were divided
into four groups (n=10). GII (+ve control) was the infected nontreated
group (infected control), GIII (SC treated): MSCs-treated (3 x
106 MSCs in 0.1 mL of PBS via the tail vein), GIV (ALB treated)
albendazole-treated (100 mg/kg/d once orally for 5 successive days)
and GV (SC/ALB): MSCs+ albendazole-treated. Treatment was
commenced 4 weeks p.i. and the experiment was terminated four
weeks after administration of the last doses of the tested drugs. The
brain tissue of each mouse was subjected for histopathological,
immunohistochemical studies (caspase-3, TGF-β), detection or T.
canis DNA by real-time PCR and gene expression the biomarkers of
brain damage (S100B, GFAP) by real- time RT-PCR. Moreover,
homing of iron oxide-labelled MSCs in brain tissues was assessed by
Prussian blue stain.